Professor Frank Gannon

Professor Frank Gannon - Chairman

Professor Frank Gannon is the Director and CEO of the QIMR Berghofer Medical Research Institute. He joined QIMR Berghofer in January 2011, having been Director General and board member of Science Foundation Ireland (SFI) since 2007.

He obtained his PhD from the University of Leicester, England in 1973 and worked subsequently in the USA, France, Ireland and Germany where he was Executive Director of the European Molecular Biology Organisation (EMBO) from 1994-2007.  He has been on the Scientific Advisory Boards of multiple institutes and Industries world-wide.

His major research interest is the regulation of gene expression by the oestrogen receptor, which plays a major role in breast and endometrial cancer. These studies have provided leads to novel treatments or therapeutic approaches to these and other cancers and have resulted in the establishment of two spin-off companies.

Donna Hancock
Non-Executive Director

Donna Hancock - Non-Executive Director

Donna Hancock is the Chief Operating Officer, Secretary to QIMR Berghofer Council, and heads the Institute’s Support Division. She holds a Bachelor of Commerce from Newcastle University and a Masters in Business Administration from the University of Melbourne.

She has an extensive background in finance, business planning, business development, systems development and commercial management. Prior to joining QIMR Berghofer, Donna worked for more than 20 years as a senior executive with BHP Billiton.

Donna is a director of Q-Pharm Pty Ltd, a member of the Australia India Business Council Women’s Executive Committee, a former member of the Medical Board of Australia (Qld Registrations Committee) and a former member of the Pharmacists Board of Queensland.

Michael Creevey
Non-Executive Director

Michael Creevey – Non-Executive Director

Michael has a technical background with degrees in computer science and electrical engineering. Following university he founded and sold various tech start-ups. After 10 years he made a conscious move into the biotechnology sector eventually becoming a General Manager of Research Support and Governance at the QIMR Berghofer Medical Research Institute. Following a short period as Q-Pharm's interim CEO, Michael has now establishing a new spin-out company in digital health,  Endpoint IQ.

Mr Chris Coyne
Non-Executive Director

Mr Chris Coyne – Non-Executive Director

Mr Coyne is Deputy Chair of the QIMR Berghofer Council

Mr Coyne is a solicitor of the Supreme Court of Queensland and an accredited specialist in the field of Commercial Litigation, specialising in insurance law, health law, corporate governance and risk management. Following his admission as a solicitor in 1979 he practised law in Brisbane and was a partner in the national law firm Clayton Utz from 1984 to 2004.

Mr Coyne now practices on his own account.  He is a member of the Council of the Queensland Law Society. Mr Coyne is a Director of the Incorporated Council of Law Reporting for the State of Queensland, past president Medico-Legal Society of Queensland and Australian Insurance Law Association and former legal member Australian Health Ethics Committee.

Mr Coyne is a member of the QIMR Berghofer Executive Employment and Remuneration Committee and a Director of the Q-Pharm Pty Ltd Board (a wholly-owned subsidiary of QIMR Berghofer).

Mark Gray
Non-Executive Director

Mark Gray – Non-Executive Director

Mark is an accomplished company director, with extensive experience on commercial, not-for-profit and government Boards. He is currently the Chairman of NSX-listed Sugar Terminals Limited; Chairman of the Queensland Board and Director of the Federal Board of the Royal Flying Doctor Service of Australia (RFDS); a Director of ASX-listed IT company Data#3 and also a Director of Queensland Cricket. Previous Directorships include Airtrain Citylink Limited, Queensland Treasury Corporation, Oaks Hotels and Resorts, Griffith University and the Queensland Art Gallery. Mark also has vast senior executive experience in investment banking and financial management with the Queensland Government, Macquarie Group and BDO. Mark is an Adjunct Professor of Economics at Queensland University and was awarded a Prime Minister’s Centenary Medal in 2003 for services to banking and finance.

Cherrell Hirst
Non-Executive Director

Dr Cherrell Hirst – Non-Executive Director

Cherrell Hirst graduated from the University of Queensland in medicine and practiced for 30 years, predominately as Director of the Wesley Breast Clinic (1984-2001) where she achieved a national reputation in the field of breast cancer screening and diagnosis.

Her interest in the value of education both in the practice of medicine and more broadly led to her appointment to the Council of the Queensland University of Technology in 1990 and she was elected Chancellor in 1994 serving until 2004. In addition Cherrell served on the Board of Trustees at the Brisbane Girls Grammar School from 1990 to 2006 and was chair from 1996. These were both honorary positions.

Cherrell has pursued a career as a professional non-executive director since 2001 and has served as a director on a wide variety of corporate entities across the finance, insurance, biotechnology, arts and education sectors. She currently serves as a non-executive director on the Gold Coast Hospital and Health Service and Bolton Clarke Pty Ltd and until very recently Medibank Private Ltd and ImpediMed Ltd. She is chairman of Factor Therapeutics Ltd and of the Advisory Board of the Institute of Molecular Biosciences at the University of Queensland. In addition she serves on a number of State Committees in the health and biotechnology areas.

In recognition of her work in the fields of breast cancer and education, Cherrell has been awarded four honorary doctorates, a Centenary Medal (2003) and the title of Officer of the Order of Australia (AO) (1998). She was named Queenslander of the Year in 1995 and is an elected member of the Academy of Technological Sciences and Engineering. She was awarded the Queensland AICD Gold Medal in 2015.